---
title: "Immunic publishes investor presentation outlining vidofludimus calcium Phase 3 program in multiple sclerosis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292623898.md"
description: "Immunic published an investor presentation detailing its Phase 3 program for vidofludimus calcium in multiple sclerosis. The lead candidate combines Nurr1 activation with DHODH inhibition. Phase 3 trials ENSURE-1 and ENSURE-2 are fully enrolled with 2,221 patients, with top-line data expected by late 2026. A U.S. NDA is targeted for mid-2027, with potential approval in 2028. Additionally, a Phase 3 program for progressive MS is in preparation."
datetime: "2026-07-14T12:19:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292623898.md)
  - [en](https://longbridge.com/en/news/292623898.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292623898.md)
---

# Immunic publishes investor presentation outlining vidofludimus calcium Phase 3 program in multiple sclerosis

-   Immunic positioned vidofludimus calcium (IMU-838) as its lead oral multiple sclerosis candidate, combining Nurr1 activation with selective DHODH inhibition. \* Phase 3 ENSURE-1 and ENSURE-2 relapsing MS trials fully enrolled with 2,221 patients; top-line data expected by year-end 2026. \* U.S. NDA submission targeted for mid-2027; potential U.S. regulatory approval projected in 2028. \* Progressive MS expansion framed around Phase 2 CALLIPER signals on disability measures; Phase 3 program described as in preparation for later in 2026. \* Funding expected into late 2027; U.S. intellectual property protection expected through 2044. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [IMUX.US](https://longbridge.com/en/quote/IMUX.US.md)

## Related News & Research

- [Immunic Updates Corporate Strategy, Highlights Vidofludimus Plans](https://longbridge.com/en/news/292732048.md)
- [Hamlet Biopharma wins US patent, nears Japan grant for HAMLET drug technology](https://longbridge.com/en/news/294053937.md)
- [Dolfines announces availability of H1 2026 revenue report](https://longbridge.com/en/news/294233994.md)
- [Myriad Genetics rebuilt its AI platform after costs ballooned. Now, it can process documents in seconds.](https://longbridge.com/en/news/293976476.md)
- [Embention publishes shareholder meeting minutes for June 30, 2026 meeting](https://longbridge.com/en/news/294186429.md)